HURA

SEC source: 0000897069-26-001285 · form4.xml · nonDerivative · entry 1

Bianco James A. · CIK 0001198554 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,173,307

F1 · kind: Represents gifts to adult sons who do not share same household with reporting person.

SEC source: 0000897069-26-000360 · form4.xml · derivative · entry 1

Hoffman Robert E. · CIK 0001166288 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 156,240

Underlying: Common Stock · 156,240 shares

Expires 2036-02-12

F1 · date: Represents an annual option grant under the TuHURA Biosciences, Inc. 2024 Equity Incentive Plan. One-third of the stock options become exercisable on the first, second, and third anniversaries of February 12, 2026.

F1 · derivative.exercise_date: Represents an annual option grant under the TuHURA Biosciences, Inc. 2024 Equity Incentive Plan. One-third of the stock options become exercisable on the first, second, and third anniversaries of February 12, 2026.

SEC source: 0000897069-26-000369 · form4.xml · derivative · entry 1

Tendler Craig · CIK 0002061924 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 156,240

Underlying: Common Stock · 156,240 shares

Expires 2036-02-12

F1 · date: Represents an annual option grant under the TuHURA Biosciences, Inc. 2024 Equity Incentive Plan. One-third of the stock options become exercisable on the first, second, and third anniversaries of February 12, 2026.

F1 · derivative.exercise_date: Represents an annual option grant under the TuHURA Biosciences, Inc. 2024 Equity Incentive Plan. One-third of the stock options become exercisable on the first, second, and third anniversaries of February 12, 2026.

SEC source: 0000897069-26-000367 · form4.xml · derivative · entry 1

Ng George K · CIK 0001638744 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 156,240

Underlying: Common Stock · 156,240 shares

Expires 2036-02-12

F1 · date: Represents an annual option grant under the TuHURA Biosciences, Inc. 2024 Equity Incentive Plan. One-third of the stock options become exercisable on the first, second, and third anniversaries of February 12, 2026.

F1 · derivative.exercise_date: Represents an annual option grant under the TuHURA Biosciences, Inc. 2024 Equity Incentive Plan. One-third of the stock options become exercisable on the first, second, and third anniversaries of February 12, 2026.

SEC source: 0000897069-26-000365 · form4.xml · derivative · entry 1

MANUSO JAMES S J · CIK 0001236365 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 156,240

Underlying: Common Stock · 156,240 shares

Expires 2036-02-12

F1 · date: Represents an annual option grant under the TuHURA Biosciences, Inc. 2024 Equity Incentive Plan. One-third of the stock options become exercisable on the first, second, and third anniversaries of February 12, 2026.

F1 · derivative.exercise_date: Represents an annual option grant under the TuHURA Biosciences, Inc. 2024 Equity Incentive Plan. One-third of the stock options become exercisable on the first, second, and third anniversaries of February 12, 2026.

SEC source: 0000897069-26-000363 · form4.xml · derivative · entry 1

List Alan · CIK 0001858530 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 156,240

Underlying: Common Stock · 156,240 shares

Expires 2036-02-12

F1 · date: Represents an annual option grant under the TuHURA Biosciences, Inc. 2024 Equity Incentive Plan. One-third of the stock options become exercisable on the first, second, and third anniversaries of February 12, 2026.

F1 · derivative.exercise_date: Represents an annual option grant under the TuHURA Biosciences, Inc. 2024 Equity Incentive Plan. One-third of the stock options become exercisable on the first, second, and third anniversaries of February 12, 2026.

SEC source: 0000897069-26-000112 · form4.xml · derivative · entry 1

Dearborn Dan · CIK 0001975443 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 273,696

Underlying: Common Stock · 273,696 shares

Expires 2036-01-06

F1 · derivative.exercise_date: Represents a supplemental option grant to the option grant previously made in December 2025. One-third of the stock options become exercisable on the first, second, and third anniversary of January 6, 2025.

SEC source: 0000897069-26-000111 · form4.xml · derivative · entry 1

Bianco James A. · CIK 0001198554 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 610,332

Underlying: Common Stock · 610,332 shares

Expires 2036-01-06

F1 · derivative.exercise_date: Represents a supplemental option grant to the option grant previously made in December 2025. One-third of the stock options become exercisable on the first, second, and third anniversary of January 6, 2025.

SEC source: 0000897069-25-001809 · form4.xml · derivative · entry 1

Dearborn Dan · CIK 0001975443 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,531,367

Underlying: Common Stock · 1,531,367 shares

Expires 2035-12-12

F1 · derivative.exercise_date: One-third of the stock options become exercisable on the first, second, and third anniversary of December 12, 2025.

SEC source: 0000897069-25-001807 · form4.xml · derivative · entry 1

Bianco James A. · CIK 0001198554 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,414,891

Underlying: Common Stock · 3,414,891 shares

Expires 2035-12-12

F1 · derivative.exercise_date: One-third of the stock options become exercisable on the first, second, and third anniversary of December 12, 2025.

SEC source: 0000897069-25-000664 · form4.xml · derivative · entry 1

Tendler Craig · CIK 0002061924 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 151,883

Underlying: Common Stock · 151,883 shares

Expires 2035-03-10

F1 · derivative.exercise_date: One-third of the stock options become exercisable on the first, second, and third anniversary of March 10, 2025.

SEC source: 0000897069-25-000037 · form4.xml · derivative · entry 1

Hoffman Robert E. · CIK 0001166288 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 51,275

Underlying: Common Stock · 51,275 shares

Expires 2035-01-02

F1 · date: Represents an annual option grant under the TuHURA Biosciences, Inc. Non-Employee Director Compensation Program. One-third of the stock options become exercisable on the first, second, and third anniversaries of January 2, 2025.

F1 · derivative.exercise_date: Represents an annual option grant under the TuHURA Biosciences, Inc. Non-Employee Director Compensation Program. One-third of the stock options become exercisable on the first, second, and third anniversaries of January 2, 2025.

SEC source: 0000897069-25-000031 · form4.xml · derivative · entry 1

Ng George K · CIK 0001638744 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 51,275

Underlying: Common Stock · 51,275 shares

Expires 2035-01-02

F1 · date: Represents an annual option grant under the TuHURA Biosciences, Inc. Non-Employee Director Compensation Program. One-third of the stock options become exercisable on the first, second, and third anniversaries of January 2, 2025.

F1 · derivative.exercise_date: Represents an annual option grant under the TuHURA Biosciences, Inc. Non-Employee Director Compensation Program. One-third of the stock options become exercisable on the first, second, and third anniversaries of January 2, 2025.

SEC source: 0000897069-25-000035 · form4.xml · derivative · entry 1

MANUSO JAMES S J · CIK 0001236365 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 59,590

Underlying: Common Stock · 59,590 shares

Expires 2035-01-02

F1 · date: Represents an annual option grant under the TuHURA Biosciences, Inc. Non-Employee Director Compensation Program. One-third of the stock options become exercisable on the first, second, and third anniversaries of January 2, 2025.

F1 · derivative.exercise_date: Represents an annual option grant under the TuHURA Biosciences, Inc. Non-Employee Director Compensation Program. One-third of the stock options become exercisable on the first, second, and third anniversaries of January 2, 2025.

SEC source: 0000897069-25-000033 · form4.xml · derivative · entry 1

List Alan · CIK 0001858530 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 51,275

Underlying: Common Stock · 51,275 shares

Expires 2035-01-02

F1 · date: Represents an annual option grant under the TuHURA Biosciences, Inc. Non-Employee Director Compensation Program. One-third of the stock options become exercisable on the first, second, and third anniversaries of January 2, 2025.

F1 · derivative.exercise_date: Represents an annual option grant under the TuHURA Biosciences, Inc. Non-Employee Director Compensation Program. One-third of the stock options become exercisable on the first, second, and third anniversaries of January 2, 2025.

SEC source: 0000897069-24-002166 · form4.xml · derivative · entry 1

Bianco James A. · CIK 0001198554 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,065,990

Underlying: Common Stock · 1,065,990 shares

Expires 2034-11-12

F1 · derivative.exercise_date: One-third of the stock options become exercisable on the first, second, and third anniversary of November 12, 2024.

SEC source: 0000897069-24-002164 · form4.xml · derivative · entry 1

Dearborn Dan · CIK 0001975443 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 489,848

Underlying: Common Stock · 489,848 shares

Expires 2034-11-12

F1 · derivative.exercise_date: One-third of the stock options become exercisable on the first, second, and third anniversary of November 12, 2024.

SEC source: 0000897069-24-002015 · form4.xml · derivative · entry 1

Yamashita Dennis · CIK 0002039412 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 196,790

Underlying: Common Stock · 196,790 shares

Expires 2034-01-19

F1 · date: Securities issued upon closing of the transactions contemplated by the Agreement and Plan of Merger, dated as of April 2, 2024 (the "Merger Agreement"), among the Issuer (fka "Kintara Therapeutics, Inc."), Kayak Mergeco, Inc., a Delaware corporation and wholly owned subsidiary of Issuer ("Merger Sub"), and TuHURA Biosciences, Inc., a Delaware corporation ("Private TuHURA"). Under the terms of the Merger Agreement, on October 18, 2024, Merger Sub merged with and into Private TuHURA (the "Merger") with Private TuHURA surviving the Merger as a wholly owned subsidiary of the Issuer. Upon the closing of the Merger, securities of Private TuHURA were converted into the right to receive securities of the Issuer as set forth in the Merger Agreement. The Issuer subsequently changed its name to "TuHURA Biosciences, Inc."

F2 · derivative.exercise_date: One-third of the stock options become exercisable on the first, second, and third anniversary of January 19, 2024.

SEC source: 0000897069-24-002011 · form4.xml · derivative · entry 3

Ng George K · CIK 0001638744 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,553

Underlying: Common Stock · 13,553 shares

Expires 2034-02-28

F1 · date: Securities issued upon closing of the transactions contemplated by the Agreement and Plan of Merger, dated as of April 2, 2024 (the "Merger Agreement"), among the Issuer (fka "Kintara Therapeutics, Inc."), Kayak Mergeco, Inc., a Delaware corporation and wholly owned subsidiary of Issuer ("Merger Sub"), and TuHURA Biosciences, Inc., a Delaware corporation ("Private TuHURA"). Under the terms of the Merger Agreement, on October 18, 2024, Merger Sub merged with and into Private TuHURA (the "Merger") with Private TuHURA surviving the Merger as a wholly owned subsidiary of the Issuer. Upon the closing of the Merger, securities of Private TuHURA were converted into the right to receive securities of the Issuer as set forth in the Merger Agreement. The Issuer subsequently changed its name to "TuHURA Biosciences, Inc."

SEC source: 0000897069-24-002011 · form4.xml · derivative · entry 2

Ng George K · CIK 0001638744 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,553

Underlying: Common Stock · 13,553 shares

Expires 2033-01-16

F1 · date: Securities issued upon closing of the transactions contemplated by the Agreement and Plan of Merger, dated as of April 2, 2024 (the "Merger Agreement"), among the Issuer (fka "Kintara Therapeutics, Inc."), Kayak Mergeco, Inc., a Delaware corporation and wholly owned subsidiary of Issuer ("Merger Sub"), and TuHURA Biosciences, Inc., a Delaware corporation ("Private TuHURA"). Under the terms of the Merger Agreement, on October 18, 2024, Merger Sub merged with and into Private TuHURA (the "Merger") with Private TuHURA surviving the Merger as a wholly owned subsidiary of the Issuer. Upon the closing of the Merger, securities of Private TuHURA were converted into the right to receive securities of the Issuer as set forth in the Merger Agreement. The Issuer subsequently changed its name to "TuHURA Biosciences, Inc."

SEC source: 0000897069-24-002011 · form4.xml · derivative · entry 1

Ng George K · CIK 0001638744 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 35,780

Underlying: Common Stock · 35,780 shares

Expires 2030-02-06

F1 · date: Securities issued upon closing of the transactions contemplated by the Agreement and Plan of Merger, dated as of April 2, 2024 (the "Merger Agreement"), among the Issuer (fka "Kintara Therapeutics, Inc."), Kayak Mergeco, Inc., a Delaware corporation and wholly owned subsidiary of Issuer ("Merger Sub"), and TuHURA Biosciences, Inc., a Delaware corporation ("Private TuHURA"). Under the terms of the Merger Agreement, on October 18, 2024, Merger Sub merged with and into Private TuHURA (the "Merger") with Private TuHURA surviving the Merger as a wholly owned subsidiary of the Issuer. Upon the closing of the Merger, securities of Private TuHURA were converted into the right to receive securities of the Issuer as set forth in the Merger Agreement. The Issuer subsequently changed its name to "TuHURA Biosciences, Inc."

SEC source: 0000897069-24-002007 · form4.xml · derivative · entry 2

List Alan · CIK 0001858530 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,553

Underlying: Common Stock · 13,553 shares

Expires 2034-02-28

F1 · date: Securities issued upon closing of the transactions contemplated by the Agreement and Plan of Merger, dated as of April 2, 2024 (the "Merger Agreement"), among the Issuer (fka "Kintara Therapeutics, Inc."), Kayak Mergeco, Inc., a Delaware corporation and wholly owned subsidiary of Issuer ("Merger Sub"), and TuHURA Biosciences, Inc., a Delaware corporation ("Private TuHURA"). Under the terms of the Merger Agreement, on October 18, 2024, Merger Sub merged with and into Private TuHURA (the "Merger") with Private TuHURA surviving the Merger as a wholly owned subsidiary of the Issuer. Upon the closing of the Merger, securities of Private TuHURA were converted into the right to receive securities of the Issuer as set forth in the Merger Agreement. The Issuer subsequently changed its name to "TuHURA Biosciences, Inc."

SEC source: 0000897069-24-002007 · form4.xml · derivative · entry 1

List Alan · CIK 0001858530 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,553

Underlying: Common Stock · 13,553 shares

Expires 2033-01-16

F1 · date: Securities issued upon closing of the transactions contemplated by the Agreement and Plan of Merger, dated as of April 2, 2024 (the "Merger Agreement"), among the Issuer (fka "Kintara Therapeutics, Inc."), Kayak Mergeco, Inc., a Delaware corporation and wholly owned subsidiary of Issuer ("Merger Sub"), and TuHURA Biosciences, Inc., a Delaware corporation ("Private TuHURA"). Under the terms of the Merger Agreement, on October 18, 2024, Merger Sub merged with and into Private TuHURA (the "Merger") with Private TuHURA surviving the Merger as a wholly owned subsidiary of the Issuer. Upon the closing of the Merger, securities of Private TuHURA were converted into the right to receive securities of the Issuer as set forth in the Merger Agreement. The Issuer subsequently changed its name to "TuHURA Biosciences, Inc."

SEC source: 0000897069-24-002003 · form4.xml · derivative · entry 2

MANUSO JAMES S J · CIK 0001236365 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,553

Underlying: Common Stock · 13,553 shares

Expires 2034-02-28

F1 · date: Securities issued upon closing of the transactions contemplated by the Agreement and Plan of Merger, dated as of April 2, 2024 (the "Merger Agreement"), among the Issuer (fka "Kintara Therapeutics, Inc."), Kayak Mergeco, Inc., a Delaware corporation and wholly owned subsidiary of Issuer ("Merger Sub"), and TuHURA Biosciences, Inc., a Delaware corporation ("Private TuHURA"). Under the terms of the Merger Agreement, on October 18, 2024, Merger Sub merged with and into Private TuHURA (the "Merger") with Private TuHURA surviving the Merger as a wholly owned subsidiary of the Issuer. Upon the closing of the Merger, securities of Private TuHURA were converted into the right to receive securities of the Issuer as set forth in the Merger Agreement. The Issuer subsequently changed its name to "TuHURA Biosciences, Inc."

SEC source: 0000897069-24-002003 · form4.xml · derivative · entry 1

MANUSO JAMES S J · CIK 0001236365 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,553

Underlying: Common Stock · 13,553 shares

Expires 2033-01-16

F1 · date: Securities issued upon closing of the transactions contemplated by the Agreement and Plan of Merger, dated as of April 2, 2024 (the "Merger Agreement"), among the Issuer (fka "Kintara Therapeutics, Inc."), Kayak Mergeco, Inc., a Delaware corporation and wholly owned subsidiary of Issuer ("Merger Sub"), and TuHURA Biosciences, Inc., a Delaware corporation ("Private TuHURA"). Under the terms of the Merger Agreement, on October 18, 2024, Merger Sub merged with and into Private TuHURA (the "Merger") with Private TuHURA surviving the Merger as a wholly owned subsidiary of the Issuer. Upon the closing of the Merger, securities of Private TuHURA were converted into the right to receive securities of the Issuer as set forth in the Merger Agreement. The Issuer subsequently changed its name to "TuHURA Biosciences, Inc."

SEC source: 0000897069-24-001996 · form4.xml · derivative · entry 4

Bianco James A. · CIK 0001198554 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 191,280

Underlying: Common Stock · 191,280 shares

Expires 2034-02-28

F1 · date: Securities issued upon closing of the transactions contemplated by the Agreement and Plan of Merger, dated as of April 2, 2024 (the "Merger Agreement"), among the Issuer (fka "Kintara Therapeutics, Inc."), Kayak Mergeco, Inc., a Delaware corporation and wholly owned subsidiary of Issuer ("Merger Sub"), and TuHURA Biosciences, Inc., a Delaware corporation ("Private TuHURA"). Under the terms of the Merger Agreement, on October 18, 2024, Merger Sub merged with and into Private TuHURA (the "Merger") with Private TuHURA surviving the Merger as a wholly owned subsidiary of the Issuer. Upon the closing of the Merger, securities of Private TuHURA were converted into the right to receive securities of the Issuer as set forth in the Merger Agreement. The Issuer subsequently changed its name to "TuHURA Biosciences, Inc."

F3 · derivative.exercise_date: One-third of the stock options become exercisable on the first, second and third anniversary of February 28, 2024.

SEC source: 0000897069-24-001996 · form4.xml · derivative · entry 3

Bianco James A. · CIK 0001198554 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 71,560

Underlying: Common Stock · 71,560 shares

Expires 2033-04-07

F1 · date: Securities issued upon closing of the transactions contemplated by the Agreement and Plan of Merger, dated as of April 2, 2024 (the "Merger Agreement"), among the Issuer (fka "Kintara Therapeutics, Inc."), Kayak Mergeco, Inc., a Delaware corporation and wholly owned subsidiary of Issuer ("Merger Sub"), and TuHURA Biosciences, Inc., a Delaware corporation ("Private TuHURA"). Under the terms of the Merger Agreement, on October 18, 2024, Merger Sub merged with and into Private TuHURA (the "Merger") with Private TuHURA surviving the Merger as a wholly owned subsidiary of the Issuer. Upon the closing of the Merger, securities of Private TuHURA were converted into the right to receive securities of the Issuer as set forth in the Merger Agreement. The Issuer subsequently changed its name to "TuHURA Biosciences, Inc."

F2 · derivative.exercise_date: One-third of the stock options become exercisable on the first, second, and third anniversary of April 7, 2023.

SEC source: 0000897069-24-001996 · form4.xml · derivative · entry 2

Bianco James A. · CIK 0001198554 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 357,800

Underlying: Common Stock · 357,800 shares

Expires 2031-07-01

F1 · date: Securities issued upon closing of the transactions contemplated by the Agreement and Plan of Merger, dated as of April 2, 2024 (the "Merger Agreement"), among the Issuer (fka "Kintara Therapeutics, Inc."), Kayak Mergeco, Inc., a Delaware corporation and wholly owned subsidiary of Issuer ("Merger Sub"), and TuHURA Biosciences, Inc., a Delaware corporation ("Private TuHURA"). Under the terms of the Merger Agreement, on October 18, 2024, Merger Sub merged with and into Private TuHURA (the "Merger") with Private TuHURA surviving the Merger as a wholly owned subsidiary of the Issuer. Upon the closing of the Merger, securities of Private TuHURA were converted into the right to receive securities of the Issuer as set forth in the Merger Agreement. The Issuer subsequently changed its name to "TuHURA Biosciences, Inc."

SEC source: 0000897069-24-001996 · form4.xml · nonDerivative · entry 1

Bianco James A. · CIK 0001198554 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,323,307

F1 · date: Securities issued upon closing of the transactions contemplated by the Agreement and Plan of Merger, dated as of April 2, 2024 (the "Merger Agreement"), among the Issuer (fka "Kintara Therapeutics, Inc."), Kayak Mergeco, Inc., a Delaware corporation and wholly owned subsidiary of Issuer ("Merger Sub"), and TuHURA Biosciences, Inc., a Delaware corporation ("Private TuHURA"). Under the terms of the Merger Agreement, on October 18, 2024, Merger Sub merged with and into Private TuHURA (the "Merger") with Private TuHURA surviving the Merger as a wholly owned subsidiary of the Issuer. Upon the closing of the Merger, securities of Private TuHURA were converted into the right to receive securities of the Issuer as set forth in the Merger Agreement. The Issuer subsequently changed its name to "TuHURA Biosciences, Inc."

SEC source: 0000897069-24-001992 · form4.xml · derivative · entry 5

Dearborn Dan · CIK 0001975443 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 66,658

Underlying: Common Stock · 66,658 shares

Expires 2034-02-28

F1 · date: Securities issued upon closing of the transactions contemplated by the Agreement and Plan of Merger, dated as of April 2, 2024 (the "Merger Agreement"), among the Issuer (fka "Kintara Therapeutics, Inc."), Kayak Mergeco, Inc., a Delaware corporation and wholly owned subsidiary of Issuer ("Merger Sub"), and TuHURA Biosciences, Inc., a Delaware corporation ("Private TuHURA"). Under the terms of the Merger Agreement, on October 18, 2024, Merger Sub merged with and into Private TuHURA (the "Merger") with Private TuHURA surviving the Merger as a wholly owned subsidiary of the Issuer. Upon the closing of the Merger, securities of Private TuHURA were converted into the right to receive securities of the Issuer as set forth in the Merger Agreement. The Issuer subsequently changed its name to "TuHURA Biosciences, Inc."

F4 · derivative.exercise_date: One-third of the stock options become exercisable on the first, second, and third anniversary of February 28, 2024.

SEC source: 0000897069-24-001992 · form4.xml · derivative · entry 4

Dearborn Dan · CIK 0001975443 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,744

Underlying: Common Stock · 15,744 shares

Expires 2033-04-07

F1 · date: Securities issued upon closing of the transactions contemplated by the Agreement and Plan of Merger, dated as of April 2, 2024 (the "Merger Agreement"), among the Issuer (fka "Kintara Therapeutics, Inc."), Kayak Mergeco, Inc., a Delaware corporation and wholly owned subsidiary of Issuer ("Merger Sub"), and TuHURA Biosciences, Inc., a Delaware corporation ("Private TuHURA"). Under the terms of the Merger Agreement, on October 18, 2024, Merger Sub merged with and into Private TuHURA (the "Merger") with Private TuHURA surviving the Merger as a wholly owned subsidiary of the Issuer. Upon the closing of the Merger, securities of Private TuHURA were converted into the right to receive securities of the Issuer as set forth in the Merger Agreement. The Issuer subsequently changed its name to "TuHURA Biosciences, Inc."

F3 · derivative.exercise_date: One-third of the stock options become exercisable on the first, second, and third anniversary of April 7, 2023.

SEC source: 0000897069-24-001992 · form4.xml · derivative · entry 3

Dearborn Dan · CIK 0001975443 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 232,570

Underlying: Common Stock · 232,570 shares

Expires 2032-11-15

F1 · date: Securities issued upon closing of the transactions contemplated by the Agreement and Plan of Merger, dated as of April 2, 2024 (the "Merger Agreement"), among the Issuer (fka "Kintara Therapeutics, Inc."), Kayak Mergeco, Inc., a Delaware corporation and wholly owned subsidiary of Issuer ("Merger Sub"), and TuHURA Biosciences, Inc., a Delaware corporation ("Private TuHURA"). Under the terms of the Merger Agreement, on October 18, 2024, Merger Sub merged with and into Private TuHURA (the "Merger") with Private TuHURA surviving the Merger as a wholly owned subsidiary of the Issuer. Upon the closing of the Merger, securities of Private TuHURA were converted into the right to receive securities of the Issuer as set forth in the Merger Agreement. The Issuer subsequently changed its name to "TuHURA Biosciences, Inc."

F2 · derivative.exercise_date: One-third of the stock options become exercisable on the first, second, and third anniversary of November 15, 2023.

SEC source: 0000897069-24-001992 · form4.xml · derivative · entry 2

Dearborn Dan · CIK 0001975443 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 68,438

Underlying: Common Stock · 68,438 shares

Expires 2026-12-20

F1 · date: Securities issued upon closing of the transactions contemplated by the Agreement and Plan of Merger, dated as of April 2, 2024 (the "Merger Agreement"), among the Issuer (fka "Kintara Therapeutics, Inc."), Kayak Mergeco, Inc., a Delaware corporation and wholly owned subsidiary of Issuer ("Merger Sub"), and TuHURA Biosciences, Inc., a Delaware corporation ("Private TuHURA"). Under the terms of the Merger Agreement, on October 18, 2024, Merger Sub merged with and into Private TuHURA (the "Merger") with Private TuHURA surviving the Merger as a wholly owned subsidiary of the Issuer. Upon the closing of the Merger, securities of Private TuHURA were converted into the right to receive securities of the Issuer as set forth in the Merger Agreement. The Issuer subsequently changed its name to "TuHURA Biosciences, Inc."

SEC source: 0000897069-24-001992 · form4.xml · derivative · entry 1

Dearborn Dan · CIK 0001975443 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 33,991

Underlying: Common Stock · 33,991 shares

Expires 2026-01-17

F1 · date: Securities issued upon closing of the transactions contemplated by the Agreement and Plan of Merger, dated as of April 2, 2024 (the "Merger Agreement"), among the Issuer (fka "Kintara Therapeutics, Inc."), Kayak Mergeco, Inc., a Delaware corporation and wholly owned subsidiary of Issuer ("Merger Sub"), and TuHURA Biosciences, Inc., a Delaware corporation ("Private TuHURA"). Under the terms of the Merger Agreement, on October 18, 2024, Merger Sub merged with and into Private TuHURA (the "Merger") with Private TuHURA surviving the Merger as a wholly owned subsidiary of the Issuer. Upon the closing of the Merger, securities of Private TuHURA were converted into the right to receive securities of the Issuer as set forth in the Merger Agreement. The Issuer subsequently changed its name to "TuHURA Biosciences, Inc."

SEC source: 0001493152-23-031537 · ownership.xml · derivative · entry 1

Hoffman Robert E. · CIK 0001166288 · Director · President, CEO and Interim CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 23,142

Underlying: Common Stock · 23,142 shares

Expires 2033-08-30

F1 · derivative.exercise_date: The option award was made to reporting person pursuant to the 2017 Omnibus Equity Incentive Plan, as amended. Subject to continued employment, 25% of the options vest on August 30, 2024, with the remaining shares vesting in 36 equal monthly installments commencing on September 30, 2024.

SEC source: 0001493152-23-031538 · ownership.xml · derivative · entry 1

Johnson Laura L. · CIK 0001589362 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,500

Underlying: Common Stock · 8,500 shares

Expires 2033-08-30

F1 · derivative.exercise_date: The option award was made to reporting person pursuant to the 2017 Omnibus Equity Incentive Plan, as amended. Subject to continued service, the options vest in 12 equal monthly installments commencing on September 30, 2023.

SEC source: 0001493152-23-031535 · ownership.xml · derivative · entry 1

FAVORITO TAMARA A · CIK 0001288232 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,500

Underlying: Common Stock · 8,500 shares

Expires 2033-08-30

F1 · derivative.exercise_date: The option award was made to reporting person pursuant to the 2017 Omnibus Equity Incentive Plan, as amended. Subject to continued service, the options vest in 12 equal monthly installments commencing on September 30, 2023.

SEC source: 0001493152-23-031536 · ownership.xml · derivative · entry 1

TOTH ROBERT JOSEPH JR · CIK 0001585020 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,500

Underlying: Common Stock · 8,500 shares

Expires 2033-08-30

F1 · derivative.exercise_date: The option award was made to reporting person pursuant to the 2017 Omnibus Equity Incentive Plan, as amended. Subject to continued service, the options vest in 12 equal monthly installments commencing on September 30, 2023.

SEC source: 0001493152-23-031534 · ownership.xml · derivative · entry 1

Brown Dennis M · CIK 0001569520 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,175

Underlying: Common Stock · 10,175 shares

Expires 2033-08-30

F1 · derivative.exercise_date: The option award was made to reporting person pursuant to the 2017 Omnibus Equity Incentive Plan, as amended. Subject to continued employment, 25% of the options vest on August 30, 2024, with the remaining shares vesting in 36 equal monthly installments commencing on September 30, 2024.

SEC source: 0001493152-23-019950 · ownership.xml · nonDerivative · entry 1

Hoffman Robert E. · CIK 0001166288 · Director · President, CEO, and CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 68,902

F1 · shares: The Reporting Person was granted 59,800 restricted stock units, which will be settled in shares of the Issuer's common stock. The restricted stock units vest in full on June 1, 2024.

SEC source: 0001493152-23-000860 · ownership.xml · nonDerivative · entry 1

Brown Dennis M · CIK 0001569520 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,302

F1 · balance_after: Includes 4,801 restricted stock units that are unvested.

SEC source: 0001493152-22-021170 · ownership.xml · derivative · entry 2

Hoffman Robert E. · CIK 0001166288 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,200,634

Underlying: Common Stock · 1,200,634 shares

Expires 2022-08-02

F2 · derivative.exercise_date: The option vests as to 25% on August 1, 2023 with the remainder to vest in 36 equal monthly installments thereafter.

SEC source: 0001493152-22-021170 · ownership.xml · nonDerivative · entry 1

Hoffman Robert E. · CIK 0001166288 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 455,145

F1 · shares: The Reporting Person was granted 400,145 restricted stock units, which will be settled in shares of the Issuer's common stock. The restricted stock units vest in 4 equal annual installments beginning on August 1, 2023.

SEC source: 0001493152-22-021172 · ownership.xml · derivative · entry 2

Praill Anthony Scott · CIK 0001332948 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 720,260

Underlying: Common Stock · 720,260 shares

Expires 2022-08-02

F2 · derivative.exercise_date: The option vests as to 25% on August 1, 2023 with the remainder to vest in 36 equal monthly installments thereafter.

SEC source: 0001493152-22-021172 · ownership.xml · nonDerivative · entry 1

Praill Anthony Scott · CIK 0001332948 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 277,273

F1 · shares: The Reporting Person was granted 240,087 restricted stock units, which will be settled in shares of the Issuer's common stock. The restricted stock units vest in 4 equal annual installments beginning on August 1, 2023.

SEC source: 0001493152-22-021171 · ownership.xml · derivative · entry 3

Brown Dennis M · CIK 0001569520 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 720,260

Underlying: Common Stock · 720,260 shares

Expires 2022-08-02

F3 · derivative.exercise_date: The option vests as to 25% on August 1, 2023 with the remainder to vest in 36 equal monthly installments thereafter.

SEC source: 0001493152-22-021171 · ownership.xml · nonDerivative · entry 1

Brown Dennis M · CIK 0001569520 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 246,905

F1 · shares: The Reporting Person was granted 240,087 restricted stock units, which will be settled in shares of the Issuer's common stock. The restricted stock units vest in 4 equal annual installments beginning on August 1, 2023.

SEC source: 0001493152-22-018526 · ownership.xml · derivative · entry 1

Johnson Laura L. · CIK 0001589362 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 100,000

Underlying: Common Stock · 100,000 shares

Expires 2032-07-01

F1 · derivative.exercise_date: The option award was made to reporting person pursuant to the 2017 Omnibus Equity Incentive Plan, as amended. Subject to continued service, the options vest in 12 equal monthly installments commencing on August 1, 2022.

SEC source: 0001493152-22-018527 · ownership.xml · derivative · entry 1

TOTH ROBERT JOSEPH JR · CIK 0001585020 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 100,000

Underlying: Common Stock · 100,000 shares

Expires 2032-07-01

F1 · derivative.exercise_date: The option award was made to reporting person pursuant to the 2017 Omnibus Equity Incentive Plan, as amended. Subject to continued service, the options vest in 12 equal monthly installments commencing on August 1, 2022.

SEC source: 0001493152-22-018529 · ownership.xml · derivative · entry 1

SEYMOUR TAMARA A · CIK 0001288232 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 100,000

Underlying: Common Stock · 100,000 shares

Expires 2032-07-01

F1 · derivative.exercise_date: The option award was made to reporting person pursuant to the 2017 Omnibus Equity Incentive Plan, as amended. Subject to continued service, the options vest in 12 equal monthly installments commencing on August 1, 2022.